HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.

AbstractINTRODUCTION:
Neurotensin receptor 1 (NTR1) is overexpressed in many cancer types. Neurotensin (NT), a 13 amino acid peptide, is the native ligand for NTR1 and exhibits high (nM) affinity to the receptor. Many laboratories have been investigating the development of diagnostic and therapeutic radiopharmaceuticals for NTR1-positive cancers based on the NT peptide. To improve the biological performance for targeting NTR1, we proposed NT analogs with a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelation system and different lengths of spacers.
METHODS:
We synthesized four NTR1-targeted conjugates with spacer lengths from 0 to 9 atoms (null (N0), β-Ala-OH (N1), 5-Ava-OH (N2), and 8-Aoc-OH (N3)) between the DOTA and the pharmacophore. In vitro competitive binding, internalization and efflux studies were performed on all four NT analogs. Based on these findings, metabolism studies were carried out on our best performing conjugate, (177)Lu-N1. Lastly, in vivo biodistribution and SPECT/CT imaging studies were performed using (177)Lu-N1 in an HT-29 xenograft mouse model.
RESULTS:
As shown in the competitive binding assays, the NT analogs with different spacers (N1, N2 and N3) exhibited lower IC50 values than the NT analog without a spacer (N0). Furthermore, N1 revealed higher retention in HT-29 cells with more rapid internalization and slower efflux than the other NT analogs. In vivo biodistribution and SPECT/CT imaging studies of (177)Lu-N1 demonstrated excellent accumulation (3.1 ± 0.4%ID/g) in the NTR1-positive tumors at 4h post-administration.
CONCLUSIONS:
The DOTA chelation system demonstrated some modest steric inhibition of the pharmacophore. However, the insertion of a 4-atom hydrocarbon spacer group restored optimal binding affinity of the analog. The in vivo assays indicated that (177)Lu-N1 could be used for imaging and radiotherapy of NTR1-positive tumors.
AuthorsYinnong Jia, Wen Shi, Zhengyuan Zhou, Nilesh K Wagh, Wei Fan, Susan K Brusnahan, Jered C Garrison
JournalNuclear medicine and biology (Nucl Med Biol) Vol. 42 Issue 11 Pg. 816-23 (Nov 2015) ISSN: 1872-9614 [Electronic] United States
PMID26302836 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • Chelating Agents
  • Peptide Fragments
  • Receptors, Neurotensin
  • neurotensin type 1 receptor
  • Neurotensin
Topics
  • Animals
  • Binding, Competitive
  • Cell Line, Tumor
  • Chelating Agents (chemistry)
  • Drug Stability
  • HT29 Cells
  • Humans
  • Isotope Labeling
  • Mice
  • Neurotensin (chemistry, metabolism, pharmacokinetics)
  • Peptide Fragments (chemistry)
  • Protein Transport
  • Receptors, Neurotensin (metabolism)
  • Tissue Distribution
  • Tomography, Emission-Computed, Single-Photon
  • X-Ray Microtomography

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: